High Erk activity suppresses expression of the cell cycle inhibitor p27Kip1 in colorectal cancer cells

Cell Communication and Signaling

Volumn 8, Issue , 2010, Pages

  Kress, Theresia R ^a,c   Raabe, Thomas ^b   Feller, Stephan M ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79955977302     PISSN: None     EISSN: 1478811X     Source Type: Journal    
DOI: 10.1186/1478-811X-8-1     Document Type: Article

References (23)

1. Gamma-secretase inhibition combined with platinum compounds enhances cell death in a large subset of colorectal cancer cells. T Aleksic, SM Feller, Cell Commun Signal 2008 6 8 10.1186/1478-811X-6-8 18950493
2. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. AH Bild, G Yao, JT Chang, Q Wang, A Potti, D Chasse, MB Joshi, D Harpole, JM Lancaster, A Berchuck, et al. Nature 2006 439 353 357 10.1038/nature04296 16273092 (Pubitemid 43128862)
3. Cell growth, global phosphotyrosine elevation, and c-Met phosphorylation through Src family kinases in colorectal cancer cells. M Emaduddin, DC Bicknell, WF Bodmer, SM Feller, Proc Natl Acad Sci USA 2008 105 2358 2362 10.1073/pnas.0712176105 18258742 (Pubitemid 351520518)
4. Coordinating ERK/MAPK signalling through scaffolds and inhibitors. W Kolch, Nat Rev Mol Cell Biol 2005 6 827 837 10.1038/nrm1743 16227978 (Pubitemid 41568732)
5. The roles of MAPKs in disease. MC Lawrence, A Jivan, C Shao, L Duan, D Goad, E Zaganjor, J Osborne, K McGlynn, S Stippec, S Earnest, et al. Cell Res 2008 18 436 442 10.1038/cr.2008.37 18347614 (Pubitemid 351498850)
6. Differential regulation and properties of MAPKs. M Raman, W Chen, MH Cobb, Oncogene 2007 26 3100 3112 10.1038/sj.onc.1210392 17496909 (Pubitemid 46763006)
7. Regulation of transendothelial migration of colon cancer cells by E-selectin-mediated activation of p38 and ERK MAP kinases. PL Tremblay, FA Auger, J Huot, Oncogene 2006 25 6563 6573 10.1038/sj.onc.1209664 16715142 (Pubitemid 44646184)
8. Downregulation of urokinase plasminogen activator receptor expression inhibits Erk signalling with concomitant suppression of invasiveness due to loss of uPAR-beta1 integrin complex in colon cancer cells. N Ahmed, K Oliva, Y Wang, M Quinn, G Rice, Br J Cancer 2003 89 374 384 10.1038/sj.bjc.6601098 12865932 (Pubitemid 36976329)
9. The MAPK signalling pathways and colorectal cancer. JY Fang, BC Richardson, Lancet Oncol 2005 6 322 327 10.1016/S1470-2045(05)70168-6 15863380 (Pubitemid 40590269)
10. MAP kinase signalling pathways in cancer. AS Dhillon, S Hagan, O Rath, W Kolch, Oncogene 2007 26 3279 3290 10.1038/sj.onc.1210421 17496922 (Pubitemid 46763021)
11. Oncogenic mutations in B-Raf: some losses yield gains. SR Hubbard, Cell 2004 116 764 766 10.1016/S0092-8674(04)00256-9 15035978 (Pubitemid 38410721)
12. Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome. P Rodriguez-Viciana, O Tetsu, WE Tidyman, AL Estep, BA Conger, MS Cruz, F McCormick, KA Rauen, Science 2006 311 1287 1290 10.1126/science.1124642 16439621 (Pubitemid 43334718)
13. The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. S Yoon, R Seger, Growth Factors 24 21 44 10.1080/02699050500284218 16393692
14. The cell-cycle regulatory protein Cks1 is required for SCF(Skp2)-mediated ubiquitinylation of p27. D Ganoth, G Bornstein, TK Ko, B Larsen, M Tyers, M Pagano, A Hershko, Nat Cell Biol 2001 3 321 324 10.1038/35060126 11231585 (Pubitemid 32201330)
15. Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation. A Montagnoli, F Fiore, E Eytan, AC Carrano, GF Draetta, A Hershko, M Pagano, Genes Dev 1999 13 1181 1189 10.1101/gad.13.9.1181 10323868 (Pubitemid 29233148)
16. Cell-free degradation of p27(kip1), a G1 cyclin-dependent kinase inhibitor, is dependent on CDK2 activity and the proteasome. H Nguyen, DM Gitig, A Koff, Mol Cell Biol 1999 19 1190 1201 9891053 (Pubitemid 29046861)
17. Pharmacologic inhibition of RAF - >MEK - >ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1. S Gysin, SH Lee, NM Dean, M McMahon, Cancer Res 2005 65 4870 4880 10.1158/0008-5472.CAN-04-2848 15930308 (Pubitemid 40740826)
18. Discovery of an oncogenic activity in p27Kip1 that causes stem cell expansion and a multiple tumor phenotype. A Besson, HC Hwang, S Cicero, SL Donovan, M Gurian-West, D Johnson, BE Clurman, MA Dyer, JM Roberts, Genes Dev 2007 21 1731 1746 10.1101/gad.1556607 17626791 (Pubitemid 47076473)
19. p27kip1: a target for tumor therapies? I Nickeleit, S Zender, U Kossatz, NP Malek, Cell Div 2007 2 13 10.1186/1747-1028-2-13 17488529 (Pubitemid 46831586)
20. Ca2+/Calmodulin-dependent Protein Kinase II Promotes Cell Cycle Progression by Directly Activating MEK1 and Subsequently Modulating p27 Phosphorylation. N Li, C Wang, Y Wu, X Liu, X Cao, J Biol Chem 2009 284 3021 3027 10.1074/jbc.M805483200 19056740
21. ERK phosphorylates p66shcA on Ser36 and subsequently regulates p27kip1 expression via the Akt-FOXO3a pathway: implication of p27kip1 in cell response to oxidative stress. Y Hu, X Wang, L Zeng, DY Cai, K Sabapathy, SP Goff, EJ Firpo, B Li, Mol Biol Cell 2005 16 3705 3718 10.1091/mbc.E05-04-0301 15930121 (Pubitemid 41077080)
22. p27 as a target for cancer therapeutics. SW Blain, HI Scher, C Cordon-Cardo, A Koff, Cancer Cell 2003 3 111 115 10.1016/S1535-6108(03)00026-6 12620406 (Pubitemid 37443384)
23. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. IM Chu, L Hengst, JM Slingerland, Nat Rev Cancer 2008 8 253 267 10.1038/nrc2347 18354415 (Pubitemid 351430863)